AFP and hepatocellular carcinoma: Amioka et al. compared the clinical outcome of ramucirumab as a later-line agent in multi-molecular targeted agent sequential therapy for unresectable HCC, and stated that ramucirumab efficiency is determined by the AFP response to ramucirumab, as well as the treatment response to prior TKI therapy [42].